“In a South Korean phase 1b/2 study of 40 participants with previously untreated HER2-positive advanced biliary tract cancer, the trastuzumab-nivolumab-gemcitabine-cisplatin regimen produced a 55% objective response rate.”

0.9938 under ledger-default@0.3.0 at snapshot 27745.

What was asked, and where it stands. Provisional until audited.

Review 25% done · 25% counted in review coverage (1 claim, 4 checks)

Share:

Checked in Galedra: score 0.99, strongly supported · not yet reviewed by anyone else “In a South Korean phase 1b/2 study of 40 participants with previously untreated HER2-positive advanced biliary tract cancer, the trastuzumab-nivolumab-gemcitabine-cisplatin regimen produced a 55%…” https://galedra.org/investigations/01a0ea95-f844-7143-9df4-175233ae7b29

“In a South Korean phase 1b/2 study of 40 participants with previously untreated HER2-positive advanced biliary tract cancer, the trastuzumab-nivolumab-gemcitabine-cisplatin regimen produced a 55% objective response rate.”

Supported · 0.9938 under ledger-default@0.3.0 at snapshot 27745 · review checks 1 of 4 · provisional until audited.

1 of 4 review checks done · 1 counted

See the evidence · Claim card